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Abstract
Background: Melatonin is extensively used in the USA in a non-regulated manner for sleep disorders. Prolonged
release melatonin (PRM) is licensed in Europe and other countries for the short term treatment of primary
insomnia in patients aged 55 years and over. However, a clear definition of the target patient population and well-
controlled studies of long-term efficacy and safety are lacking. It is known that melatonin production declines with
age. Some young insomnia patients also may have low melatonin levels. The study investigated whether older age
or low melatonin excretion is a better predictor of response to PRM, whether the efficacy observed in short-term
studies is sustained during continued treatment and the long term safety of such treatment.
Methods: Adult outpatients (791, aged 18-80 years) with primary insomnia, were treated with placebo (2 weeks)
and then randomized, double-blind to 3 weeks with PRM or placebo nightly. PRM patients continued whereas
placebo completers were re-randomized 1:1 to PRM or placebo for 26 weeks with 2 weeks of single-blind placebo
run-out. Main outcome measures were sleep latency derived from a sleep diary, Pittsburgh Sleep Quality Index
(PSQI), Quality of Life (World Health Organzaton-5) Clinical Global Impression of Improvement (CGI-I) and adverse
effects and vital signs recorded at each visit.
Results: On the primary efficacy variable, sleep latency, the effects of PRM (3 weeks) in patients with low
endogenous melatonin (6-sulphatoxymelatonin [6-SMT] ≤8 μg/night) regardless of age did not differ from the
placebo, whereas PRM significantly reduced sleep latency compared to the placebo in elderly patients regardless of
melatonin levels (-19.1 versus -1.7 min; P = 0.002). The effects on sleep latency and additional sleep and daytime
parameters that improved with PRM were maintained or enhanced over the 6-month period with no signs of
tolerance. Most adverse events were mild in severity with no clinically relevant differences between PRM and
placebo for any safety outcome.
Conclusions: The results demonstrate short- and long-term efficacy and safety of PRM in elderly insomnia patients.
Low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in
insomnia. The age cut-off for response warrants further investigation.
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Insomnia is a common disorder, the diagnosis of which
is based on a patient’s complaint of difficulty in initiat-
ing or maintaining sleep or sleep that is of inadequate
quality (non-restorative sleep). The sleep disturbance
should have been present for at least 1 month and be
associated with a negative impact on functioning the fol-
lowing day. Insomnia is the most common sleep disor-
der in the USA. About one-third of the adult population
has experienced insomnia at some time and approxi-
mately 10% have a persistent problem.
Melatonin (N-acetyl-5-methoxytryptamine) is the
major hormone produced nocturnally by the pineal
gland in a process driven by the biological clock residing
in the suprachiasmatic nuclei (SCN). Melatonin is a
sleep regulator and signal of darkness in humans [1].
Thus, the circadian rhythm in the synthesis and secre-
tion of melatonin is closely associated with the sleep
rhythm in both sighted and blind subjects [2,3]. Melato-
nin promotes sleep in humans [4,5], presumably by inhi-
biting circadian wakefulness mechanisms [6,7] and
affects the activity of brain networks compatible with
sleep induction [8,9]. Exogenous melatonin has clock-
shifting effects and may advance or delay the sleep
phase depending on the time of administration accord-
ing to the Phase-Response Curve [10].
Endogenous melatonin levels decrease with age, pre-
sumably due to an age-related decline in SCN circadian
rhythmic functions or the calcification of the pineal
gland [11-18]. Since endogenous melatonin has beneficial
effects on sleep in man and helps stabilize the physiologi-
cal circadian rhythms, including the sleep-wake cycle in
humans, decline in melatonin levels may contribute to
the common complaint of poor sleep quality seen
amongst the elderly [13,15,17]. This raised the possibility
of improving sleep in elderly patients with insomnia by
appropriately timed treatment with melatonin.
Early studies have shown an improvement of sleep in
e l d e r l yi n s o m n i ap a t i e n t sb yp r e s c r i b i n gv e r yh i g h
doses of melatonin [19]. Later studies, mostly done
with lower doses of immediate release melatonin
preparations and in younger people suggested a limited
efficacy in primary insomnia with short-term use
(4 weeks or less)[20].
Prolonged-release melatonin (PRM 2 mg), a formula-
tion that releases melatonin gradually in the gut when
administered orally in order to introduce melatonin into
the circulation over the following 8-10 h, has proven
efficacious and safe for the short-term treatment (3
weeks) of adults aged 55 years and older who have pri-
mary insomnia [21-25]. It has been licensed since June
2007 in Europe and in other countries for the short-
term treatment of primary insomnia characterized by
poor quality of sleep in patients who are aged 55 years
or above. Some young patients also may have low mela-
tonin levels and the important clinical question is
whether the population most likely to respond is defined
by age or by low melatonin levels. Another important
issue with the use of melatonin in clinical practice, con-
sidering the chronic nature of insomnia at older age, is
whether long-term use is justified and safe.
This study was therefore designed to elucidate
whether PRM efficacy is related to low endogenous mel-
atonin levels or age, which is associated with declining
melatonin production. The maintenance of efficacy and
the safety of PRM beyond the acute treatment were also
investigated.
In healthy adults, the nocturnal melatonin production
rate is normally 10 to 80 μg/night and urinary excretion
of the main melatonin metabolite, 6-sulphatoxymelato-
nin (6-SMT) is 8 to 56 μg/night but with wide variability
[11,13,16,17]. Thus, low endogenous melatonin in adults
was defined as urinary excretion of the major melatonin
metabolite of <8 μg 6-SMT per night.
Methods
Study design
This was a randomized, double-blind, parallel group
clinical trial comprising a 2-week, single-blind, placebo
run-in period (Baseline), a 3-week double-blind treat-
ment period (treatment weeks 1-3) followed by a 26-
week double-blind extension period (treatment weeks
4 to 29) in which patients were randomized to receive
PRM (Circadin® 2 mg, Neurim Pharmaceuticals Ltd, Tel
Aviv, Israel) or placebo, given orally as one tablet per
d a y2hb e f o r eb e d t i m e ,a n da2 - w e e ks i n g l e - b l i n dp l a -
cebo run-out period (withdrawal). The study protocol
and relevant documents were approved by Huntingdon
Multi-centre Research Ethics Committee, Cambridge,
UK. Participants provided written informed consent.
Study subjects
Patients were recruited from Glasgow and the surround-
ing areas (West of Scotland) and were pre-screened by
telephone using the Sleep History Questionnaire (SHQ)
within 1 month of the baseline screening visit. The SHQ
was adapted from The Management of Insomnia Guide-
lines for Clinical Practice [26]and resembled that recom-
mended by Clinical Practice Guideline - Adult Insomnia
[27,28]. Suitable patients were invited to Visit 1 during
which they were consented and assessed for inclusion.
Men and women aged between 18 and 80 years suffer-
ing from primary insomnia according to the Diagnostic
and Statistical Manual for Mental Disorders (DSM-IV)
criteria with sleep latency longer than 20 min were
included in the study.
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use of benzodiazepine or non-benzodiazepine hypnotics
within the previous 2 weeks or any psychoactive treat-
ment within the previous 3 months, sleep disorders
associated with a psychiatric disorder (for example,
depression, anxiety, dementia), sleep disorders secondary
to another medical condition (for example, sleep apnoea,
circadian rhythm sleep disorder), use of prohibited con-
comitant medication [psychotropic treatments - neuro-
leptics, antiepileptics, barbiturates, antidepressants,
anxiolytics and lithium, first generation antihistamines,
hypnotics or treatments used as a hypnotic (for example,
all benzodiazepines, zopiclone, zolpidem and zaleplon,
barbiturates, buspirone and hydroxyzine)] or excessive
alcohol consumption, any chronic medical condition
that was likely to be the cause of the sleep problem (for
example, chronic pain, benign prostatic hypertrophy) or
might interfere with the conduct of the study or a life-
style likely to interfere with sleep patterns (for example,
shift work, jet-lag).
A four-step process was used for screening out
patients with secondary sleep disorders including
depression and other sleep disorders in the study
according to DSM-IV criteria.
Step 1: The initial prescreening for primary insomnia
as defined in DSM-IV was performed on a telephone
interview and was based on the SHQ. The SHQ charac-
terizes the primary sleep complaint according to the dif-
ferential diagnostic criteria (DSM-IV and International
Classification of Diseases-10) and also helps in differen-
tiating primary insomnia from insomnia due to medical
and psychiatric disorders (including depression and
anxiety) and specific insomnia disorders such as circa-
dian rhythm disorders, movement disorders, parasom-
nias and breathing related sleep disorders.
Step 2: At the screening visit, a physical examination
was performed by a qualified clinician to exclude
patients with physical causes of insomnia.
Step 3: At the screening visit the patients went
through a detailed psychological assessment that
included the Raskin Depression scale, Covi anxiety scale
and the Mini Mental State (MMS) in order to exclude
psychiatric disorders, including depression anxiety and
dementia. In addition, a history of severe psychiatric dis-
orders, especially psychosis, anxiety and depression were
major exclusion criteria.
Step 4: Patients who were using psychotropics (neuro-
leptics, antiepileptics, barbiturates, antidepressants,
anxiolytics or lithium) in the 3 months before the study
were excluded. A urine drug screen for benzodiazepines
and morphine derivatives was undertaken at baseline.
Patients with a positive result were excluded. Hypnotic
use was monitored throughout the study. Patients were
asked at each visit whether they took a hypnotic beside
medication and were withdrawn if they did. The com-
mon analgesics used in UK for self limiting intermittent
p r o b l e m ss u c ha sh e a d a c h ef r e quently contain codeine.
Patients for whom pain was a cause of insomnia were
excluded from the study. However, due to the long-term
nature of the study intermittent use of common analge-
sics was allowed.
The screening and run-in periods were used to wash-
out previously administered medicinal products which
were incompatible with the trial, for confirmation of a
stable disease and compliance with study medication
and procedures and for the qualitative and quantitative
baseline assessments of patients. Patients with major
short-term fluctuations of their condition and non-com-
pliance with study procedures were excluded. A history
of sleep latency of >20 min, required for patients inclu-
sion, was assessed once in the telephone interview
(SHQ), confirmed at the screening and then at the base-
line visits using the PSQI [28-30]. Eligible patients
entered the baseline screening run-in period and
received 2 weeks of single-blind treatment with placebo.
Patients still eligible after the 2-week placebo run-in and
who were compliant with respect to treatment, had a
negative drug screen and correctly completed study
assessment forms were randomized in a 1:1 ratio to
receive either PRM 2 mg or placebo for 3 weeks in a
double-blind manner. Randomization was stratified by
trial site, 6-SMT levels (low ≤8 μgv e r s u sh i g h> 8μg/
night) and age group (< 65 versus ≥65 years).
After the 3-week treatment period, completing
patients were allowed to proceed into the extension per-
iod. All PRM patients stayed on PRM and all placebo
patients were randomised in a 1:1 ratio to receive either
PRM 2 mg or placebo for 26 weeks, resulting in a 3:1
ratio of PRM to placebo.
At the end of the extension period, all patients
received 2 weeks of single-blind placebo in the run-out
period to evaluate withdrawal effects. The overall dura-
tion of the study was 33 weeks.
Patients were instructed to take one tablet daily of
study medication orally, 1-2 h before going to bed (pre-
ferably between 2100 h and 2200 h) and after food, and
were asked to fill in a diary each morning, reporting on
sleep latency, sleep maintenance, total sleep time, time
g o i n gt ob e d ,s l e e po f f s e tt i m e ,r e f r e s h e do nw a k i n g
score, morning alertness score, and sleep quality in the
previous night).
The treatment period was double-blind with two paral-
lel treatment groups. Selection for a treatment group was
determined by a computer generated randomization list
in a 1:1 ratio (PRM mg to placebo). The list was con-
structed using the method of randomized permuted
blocks. Randomization was stratified by trial site, 6-SMT
levels (low/high) and age group (< 65/> 65). A centralized
Wade et al. BMC Medicine 2010, 8:51
http://www.biomedcentral.com/1741-7015/8/51
Page 3 of 18randomization system (Interactive Voice Response Sys-
tem [IVRS]) was used. Sites called the IVRS, using a toll-
free number. The patient’s status: trial site, 6-SMT level
(low excretors/high excretors) and age (< 65/>65) were
entered into the IVRS. The IVRS randomised the patients
and provided a double-blind treatment kit assignment.
By the end of the 3 week treatment period, the PRM
patients remained on the active medication and placebo
patients were randomized again for the double-blind
extension period. Selection for a treatment group was
determined by a computer generated randomization list
in a 1:1 ratio (PRM 2 mg to placebo). This procedure
was performed for all participants using the centralized
IVRS randomization system keeping the patient and the
study personnel (investigator and nurses) blind to
the allocated treatment. The list was constructed using
the method of randomized permuted blocks.
Blinding was maintained by use of a matching placebo
identical in appearance taste and smell to the active
medication and use of an independent IVRS to allocate
randomized treatment. During the 33 weeks of the
study (run-in, double-blind treatment, double-blind
extension and run-out), patients were blinded regarding
the type of medication they were receiving (placebo or
active). During the double-blind treatment and exten-
sion periods, the investigator(s) and their staff were also
blinded regarding the treatment administered (double-
blind). However, they were aware that the patient was
receiving placebo during the run-in and run-out periods.
The blinding was not to be broken (unless in an emer-
gency) until the database was locked to perform planned
analyses. The IVRS was used to break a code in case of
emergency. This was to be done only when the investi-
gator decided that knowledge of which study treatment
the patient had been randomized to, would affect the
management of an adverse experience. There were three
people for whom the blind was broken all due to a ser-
ious adverse event (SAE), two were on PRM and one
was on a placebo.
Endpoints
The main objective of this study was to assess the
effects of short-term (3-week) therapy with PRM versus
placebo on patient reported sleep latency (sleep diary) in
their natural setting, in patients with low endogenous
melatonin levels (≤8 versus >8 μg urinary 6-SMT/night)
and in elderly patients (65-80 years old). Additional
sleep and daytime parameters, safety and maintenance
of PRM efficacy and safety over a 6-month period were
also evaluated.
Efficacy variables were recorded at baseline and each
visit. PSQI [29,30] global score, component scores, and
questions 2 and 4 filled in by the investigator with the
patient; sleep diary (National Sleep Foundation diary)
parameters (daytime and night-time) were filled in by
patient each day in the morning in the 7 days preceding
each visit; World Health Organization (WHO)-5 Well-
being Index (1998 version) [31]and Clinical Global
Impression of Improvement (CGI) - Severity of Illness
Scale (CGI-S) [32] were filled in by the investigator with
the patient at screening and baseline and the improve-
ment (CGI-I) at each subsequent visit.
The PSQI has been recommended as an essential mea-
sure for global sleep and insomnia symptoms in recent
expert consensus recommendations for a standard set of
research assessments in insomnia [28]. It comprises nine
questions relating to the patient’s usual sleep habits during
the previous 2 weeks; the second and third weeks of active
treatment. It addresses possible reasons for trouble in
sleeping as well as daytime behaviour. An algorithm is
used to calculate seven component scores and these are
added to give a global PSQI score. The PSQI component
scores, Question 2 (Sleep Latency) and Question 4 (Total
Sleep Time) after 3 weeks’ double-blind treatment, and the
change from baseline levels of these parameters. It has
been shown that each of the PSQI individual component
scores measures a particular aspect of the overall construct.
Furthermore, control subjects differ from insomnia patients
in all individual components [29]. However, the correlation
between individual items and global score ranged from
0.83 (subjective sleep quality) to 0.07 (cough or snore dur-
ing sleep) [29]. In the evaluation of the drug effects it was
therefore interesting to look at each component.
Safety variables and vital signs (pulse, blood pressure)
were assessed at each visit including spontaneously
reported adverse events (AEs); unusual events and AEs
observed by the investigator. Physical examination was
performed at screening, end of run-in, after three and 29
treatment weeks and at discontinuation. An electrocar-
diograph was recorded at end of run-in, after three, seven
and 29 treatment weeks and at discontinuation. Vital
signs (pulse, blood pressure) were recorded at all visits.
Laboratory tests (haematology, biochemistry and urinaly-
sis) were assessed at screening, after three, seven and 29
treatment weeks and at discontinuation. Endocrine eva-
luations were performed at screening and after 29 treat-
ment weeks in 80 patients who were not using any
hormonal contraceptives or hormonal replacement thera-
pies and who were not suffering from any significant
endocrine disease. Cortisol was assessed at screening and
after 29 treatment weeks in 56 patients before and after
synacthen test. The Tyrer scale [33]was completed by the
investigator after 29 treatment weeks and at withdrawal.
Statistical issues
The predefined primary efficacy variable was the compar-
ison of sleep latency as measured by the sleep diary at
3 weeks treatment weeks with PRM (2 mg) or placebo in
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excretors of melatonin regardless of age (primary end-
point) and the patients aged 65-80 years, regardless of
melatonin levels. The comparison was done using a
linear regression model with terms for treatment (PRM
versus placebo), baseline sleep latency and age group
(≥65 or <65 - only for the primary endpoint). In compli-
ance with US Food Drug Administration regulatory
procedures, no correction for multiple comparisons were
performed for the primary outcome measure.
All other efficacy endpoints were pre-defined as
exploratory and aimed at confirming the results of the
primary analysis using additional instruments (for exam-
ple, PSQI) or adding information on other aspects of
the sleep and daytime consequences of the treatment
including: (1) time going to bed and sleep offset times,
sleep maintenance, total sleep time, sleep quality and
morning alertness from the sleep diaries; (2) the PSQI
global score; (3) PSQI questions 2 (sleep latency in min-
utes) and 4 (total sleep time in minutes) and the indivi-
dual PSQI components; (4) the CGI-I score assessed by
the clinician at three to 29 treatment weeks) quality of
life derived from the WHO-5 Well-being index covering
positive mood, vitality and general interests.
Our main conclusion was based on sleep latency, the
predefined primary variable. No correction was made for
multiple statistical testing for the exploratory variables.
Accordingly, the overall conclusions from the results are
based on the accumulation of evidence for between-treat-
ment differences which were, in many cases, correlated
or complementary, rather than on isolated P-values.
Short-term period
Sleep latency as recorded in the sleep diary was sum-
marized for low excretors aged 18-80 years and for
patients aged 65-80 years, at baseline after the 2-week
run-in period and after 3 weeks double-blind treatment
(actual and change from baseline) for each treatment
group and, as a whole, using descriptive statistics for
continuous variables. At each visit, the mean value of
the 7 days prior to the visit was used. Sleep latency as
measured by the sleep diary after 3 weeks double-blind
treatment was compared using a linear regression model
with terms for treatment (PRM versus placebo), baseline
sleep latency and age group (≥65 or <65 years).
The other short-term variables were summarized by
the mean values at baseline and after 3 weeks of dou-
ble-blind treatment (actual and change from baseline)
using descriptive statistics of continuous variables for
each treatment group. These included: (1) sleep diary
variables, calculated as the mean of the values recorded
in the 7 days prior to each study visit; (2) PSQI global,
individual component, question 2 and question 4 scores;
(3) WHO-5 Well-being Index score; (4) CGI-S (Visit 2)
and CGI-I (Visit 3) scores.
Long-term period
Efficacy variables were summarized by the first randomi-
zation for outcomes at baseline and treatment weeks 4-
29, or those visits at which the outcome was recorded.
Summaries are given at each visit, and for changes
between post-baseline visits and baseline. For those out-
comes recorded at withdrawal, summaries are given for
the change between treatment week 29 and withdrawal
weeks. In addition, the changes of PSQI and WHO-5
between treatment week 29 and withdrawal weeks in
the run-out period are summarized.
For efficacy outcomes measured at treatment weeks 4
to 29, a linear mixed effects model for repeated mea-
sures [MMRM] was used to compare outcomes at treat-
ment weeks 4 to 29, in relation to the treatment
currently received. For treatment week 3 measures,
treatment was defined by the first randomization; for
subsequent visits, treatment was defined by the second
randomization. Each model included a random indivi-
dual effect and assumed a general covariance structure
for the residuals over time. For each outcome, a model
was fitted which included terms for treatment, visit (as a
categorical variable), the baseline values of the outcome
measure, age group (≥65 or <65 years, except for ana-
lyses for the ≥65 years) and baseline 6-SMT (≤8o r> 8
μg/night, except for analyses of low excretors). This
model was used to estimate the global treatment effect,
with a 95% confidence interval (CI) and P-value.
For each outcome, the above model was extended by
including treatment-by-visit interaction terms. These
models were used to estimate the treatment effect at
each visit, with 95% CIs and P-values. A P-value for the
treatment-by-visit interaction is provided, based on a
likelihood ratio test. The global and visit-specific treat-
ment effect estimates and 95% CIs are provided graphi-
cally, along with the estimated mean values and 95% CIs
at each visit for each treatment group. In addition, a
model was also fitted for each outcome, including a
treatment-by-visit interaction, assuming a linear trend in
the treatment effect over Visits 3 to 7, with the treat-
ment effect changing by a fixed amount between each
consecutive pair of visits; a likelihood ratio test P-value
is given for this trend.
Safety outcomes
Adverse event data, clinical laboratory data, including
hormones, vital signs and withdrawal symptoms, were
summarized for all randomized study participants who
took at least one dose of study medication, regardless of
their subsequent participation in the study. No formal
statistical testing was performed on the safety data.
Sample size
In order to achieve 95% power at the 5% level for the
primary objective of assessing the change in sleep
latency in the Intention to Treat (ITT) low excretors at
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residual standard deviation of 40.6 min, 120 participants
were required per treatment group. Assuming equal
numbers of low and high excretors, 480 patients were
required to complete treatment Week 3. Assuming a
10% dropout rate between baseline and Week 3, 540
patients would have to be randomized at baseline. In
order to achieve 90% power at the 5% level for the first
secondary objective of assessing the change in sleep
latency in the ITT dataset of patients aged 65-80 years,
assuming a treatment effect of 14 min and a residual
standard deviation of 40.7 min, 179 patients ≥65 years
were required per group (active and placebo). Therefore,
400 patients in this age range would need to be rando-
mized at baseline. Assuming 45% of 540 patients already
randomized would be ≥65 years old (245), an additional
150 patients would need to be randomized at baseline
in this age group.
Results
Patient disposition and demographics
A total of 930 patients were enrolled into the study
between October 2006 and December 2008 and entered
the run-in period; 139 of these patients discontinued
during the run-in period. The overall disposition of the
patients in this study is summarized in Figure 1.
Of 791 patients in the short-term period, two were
not treated with study drug and were excluded from the
safety population. Of the 789 patients in the safety
population, 43 (5%) were discontinued before the end of
the 3-week treatment period. The most common rea-
sons for discontinuation were withdrawal of consent
(19, 44%), lost to follow-up (9, 21%) and discontinuation
due to an AE (5, 12%). No other reason accounted for
more than 10% of discontinuations. The pattern of dis-
continuation was similar for both treatment groups in
baseline 6-SMT, age and gender (Figure 1). The Full
Analysis Set (FAS) comprised 746 patients: 373 in the
PRM group, and 373 in the placebo group. Baseline
demography of the low excretors and 65-80 year-old
patients are depicted in Tables 1 and 2. Patient baseline
characteristics were similar between the two treatment
cohorts.
The number of patients in the low excretors (86 per
treatment group) and 65-80 year-old subgroups (PRM
137; placebo 144) of the FAS was lower than planned.
The study failed to meet the design requirements for a
95% statistical power on the primary endpoint (120 low
excretors per treatment group) and 90% power on the
first secondary endpoint (179 patients ≥65 years per
treatment group) involving sleep latency. The power
reached with these sample sizes was 86% for the patients
with low endogenous melatonin and 82% for the
patients aged 65 and older. The 722 patients (225, 31%
men; 497 women, 69%) in the FAS had a mean age of
62 years (range 20 to 80 years).
The treatment groups in the FAS were very similar
regarding gender, age, race, BMI, pulse, blood pressure,
ECG, medication use, medical history, and physical
examination abnormalities (Tables 1 and 2). Caffeine,
alcohol intake and smoking status were also generally
similar between the treatment groups. The treatment
groups were generally well balanced regarding demo-
graphic characteristics, pu l s e ,E C G ,b l o o dp r e s s u r e ,
compliance, medication use, medical history and physi-
cal examination characteristics. In this study 15.3% of
the age 65-80 population and 8.7% of the low excretor
population were confirmed to be taking common
analgesia medications that included codeine at anytime
during the study. As can be seen in the demography
(Tables 1 and 2), the patients reporting usage of codeine
containing medications were evenly randomized to PRM
and Placebo in both randomization periods.
Efficacy
Primary efficacy variable
The effects of 3 weeks treatment with PRM or placebo
on patient reported sleep latency (sleep diary) for low
excretors and elderly patients are shown in Table 3.
Sleep latency after 3 weeks of treatment was not signifi-
cant in low excretors aged 18-80 between the PRM and
placebo groups, as measured by the sleep diary, whereas
a significant difference in favour of PRM was found for
patients aged 65-80 years (-15.6 min; 95% CI -25.3 to
-6.0, P = 0.002; Table 3; Figure 2).
Other variables in the short-term period
The results of the diary, PSQI variables, CGI-I and
WHO-5 Index for low excretors aged 18-80 are depicted
in Tables 4 and 5. In the short-term period, low excre-
tors aged 18-80 years did not differ significantly in the
majority of variables but did have significantly fewer
sleep disturbances [PSQI component 5; -0.10 (-0.18,
-0.03) P = 0.008] and a significantly improved quality of
life [WHO-5 Index score; 1.21 (0.22, 2.20), P = 0.016]
with PRM compared to placebo (Tables 4 and 5).
The results of the diary, PSQI variables, CGI-I and
WHO-5 Index for patients aged 65-80 years are pre-
sented in Tables 6 and 7. In patients aged 65-80 years,
in the short-term period the PRM group showed sig-
nificant advantages in sleep latency assessed by PSQI
question 2 [-13.7 (-23.5, -3.9), P = 0.006], sleep main-
tenance assessed by the sleep diary [-0.17 (-0.33, 0.00),
P = 0.046], time going to bed (hours relative to mid-
night) assessed by the sleep diary [-0.22 (-0.39, -0.05),
P = 0.012], and quality of sleep as assessed by Global
PSQI scores [-0.64 (-1.25, -0.02), P = 0.042; Tables 6
and 7].
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The results of the long-term analyses using MMRM for
low excretors aged 18-80 are presented in Tables 4 and 5.
In the low excretors (regardless of age) a longer total
sleep time was seen with PRM compared to placebo
treated patients (estimated difference 13.1 min, 95% CI
1.0 to 25.2, P = 0.035; Table 4). PSQI global scores were
lower (improved) in the PRM group across study visits
with significant global treatment effects [-0.66 (-1.30,
-0.01), P = 0.046; Table 5]. WHO-5 Index scores were
significantly improved in PRM patients for the low
excretors [0.91 (0.16, 1.66), P = 0.017; Table 5]. CGI-I
scores were significantly lower (improved) across study
visits in the PRM group compared with placebo for
these patients [-0.25 (-0.49, -0.01), p = 0.042; Table 5].
Concerning sleep latency, there was a significant
Excluded  (n= 139 )
- Unwilling to continue 73 
- Ineligible to continue 43 
- Adverse event 8 
- Non-compliance 4 
- Lost to follow-up 3 
- Consent withdrawn 2 
- Sub-investigator withdrawn 1 
- Other / unknown 5 
Entered extension period (n= 358)     
Unwilling to continue (n= 15) 
Completed 3 weeks (n= 373) 
- Low excretors (88) 
- Age>65 (143) 
Discontinued intervention    (n= 21) 
- Adverse Event 3 
- Lost to follow-up 5 
- Unwilling to continue 11 
- Consent withdrawn 2 
Allocated to PRM (n= 395)
Received allocated intervention (n=394) 
Did not receive allocated intervention (n=1) 
Completed 3 weeks (n= 373) 
- Low excretors (90) 
- Age>65 (150)
 Discontinued intervention (n= 22) 
- Adverse Event 2 
- Ineligible to continue 3 
- Lost to follow-up 4 
- Unwilling to continue 8 
- Non-compliance 1 
- Consent withdrawn 1 
- Investigator withdrawn 1 
- Other 1 
- Unknown 1 
Allocated to placebo(n=396) 
Received allocated intervention (n=395) 
Did not receive allocated intervention(n= 1)
Entered extension period (n= 353)     
Unwilling to continue (n= 20 ) 
Allocation 
Entered 
Extension Period 
End of 3 weeks
period 
Enrollment 930 
Randomized 791 
Continued PRM (n= 358)      PRM (n= 176)
placebo(n= 177) Total receiving PRM(n= 534)
End of Extension 
Period 
Completed extension period (n= 421)     
- Low excretors (n=102) 
- Age>65 (n=167) 
Did not complete (n= 113) 
- Unwilling to continue  59 
- Adverse event    26 
- Ineligible to continue 9 
- Lost to follow-up  9 
- Non-compliance  4 
- Consent withdrawn  2 
- Investigator withdrawn 1 
- Other / unknown 3 
Completed extension period (n= 134)     
- Low excretors (n=32) 
- Age>65 (n=64) 
Did not complete (n= 43) 
- Unwilling to continue  24 
- Adverse event 10 
- Ineligible to continue 6 
- Lost to follow-up 1 
- Other / unknown 2 
Entered run-out 
Period 
Received placebo (n= 415)   
Did not receive (n=6) 
Received placebo (n= 134)
End of run-out   Completed (n= 412)     
Did not complete (n=3) 
Completed (n= 134)
Second allocation 
Figure 1 Overall study patient disposition (CONSORT).
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Page 7 of 18improvement with PRM over placebo in the low excre-
tors when measured with the PSQI question 2 [-11.6
(-22.0, -1.1) min, P = 0.030] that was less consistently
observed with the diary [-6.7 (-16.4, 3.0) min, P = 0.174;
Tables 4 and 5].
The results of the long-term analyses using MMRM
for low excretors aged 18-80 and for patients aged 65-
80 years are presented in Tables 6 and 7. In patients
aged 65-80 (regardless of melatonin excretion), sleep
latency throughout the long term period was signifi-
cantly shorter in the PRM group as assessed by the
sleep diary with a mean difference from placebo of -14.5
min (-21.4, -7.7; P < 0.001; Table 6). Similar results
were observed with sleep latency recorded by PSQI
component 2 and PSQI question 2 (Table 7) The esti-
mated treatment effect differences for sleep latency
Table 1 Baseline characteristics of the low excretor population, by treatment outcome(s): age, sex, race, height,
weight, BMI and medication use
All First randomization Second randomization
PRM Placebo PRM Placebo
N 172 86 86 127 39
Characteristic Visit
Age (years) 1 Mean (SD) 63.8 (9.3) 63.4 (9.8) 64.2 (8.8) 63.4 (9.6) 64.3 (8.3)
Sex N (%) female 128 (74.4%) 63 (73.3%) 65 (75.6%) 96 (75.6%) 28 (71.8%)
Race* N (%) white 170 (98.8%) 84 (97.7%) 86 (100.0%) 125 (98.4%) 39 (100.0%)
Height (m) 1 Mean (SD) 1.63 (0.08) 1.64 (0.09) 1.63 (0.08) 1.64 (0.09) 1.62 (0.08)
Weight (kg) 1 Mean (SD) 71.4 (13.1) 71.0 (14.0) 71.8 (12.2) 70.9 (13.4) 72.8 (12.3)
BMI (kg/m
2) 1 Mean (SD) 26.7 (4.1) 26.4 (3.9) 27.1 (4.3) 26.4 (4.0) 27.7 (4.5)
Taking any
medications
1 N (%) 17 (9.9%) 6 (7.0%) 11 (12.8%) 10 (7.9%) 6 (15.4%)
Taking codeine† 1 N (%) 29 (16.9%) 13 (15.1%) 16 (18.6%) 21 (16.5%) 8 (20.5%)
Taking codeine 2 N (%) 26 (15.1%) 16 (18.6%) 10 (11.6%) 21 (16.5%) 5 (12.8%)
Confirmed
codeine analgesic
2 N (%) 15 (8.7%) 8 (9.3%) 7 (8.1%) 11 (8.7%) 4 (10.3%)
*One patient missing observation.
†Two patients missing observations at Visit 1.
PRM, prolonged release melatonin; SD, standard deviation
Table 2 Baseline characteristics of those aged 65-80, by treatment: age, sex, race, height, weight, BMI and medication
use
All First randomization Second randomization
PRM Placebo PRM Placebo
N 281 137 144 198 75
Characteristic Visit
Age (years) 1 Mean (SD) 71.0 (4.1) 71.1 (3.8) 70.9 (4.4) 70.9 (3.9) 70.9 (4.4)
Sex N (%) female 182 (64.8%) 89 (65.0%) 93 (64.6%) 128 (64.6%) 50 (66.7%)
Race* N (%) white 280 (100.0%) 137 (100.0%) 143 (100.0%) 198 (100.0%) 74 (100.0%)
Height (m) 1 Mean (SD) 1.65 (0.09) 1.65 (0.09) 1.64 (0.09) 1.65 (0.09) 1.64 (0.09)
Weight (kg) 1 Mean (SD) 73.3 (13.0) 73.1 (14.1) 73.6 (11.8) 73.2 (13.2) 74.1 (12.6)
BMI (kg/m
2) 1 Mean (SD) 27.0 (3.8) 26.8 (3.6) 27.3 (3.9) 26.8 (3.6) 27.7 (4.2)
Taking any
medications
1 N (%) 265 (94.3%) 130 (94.9%) 135 (93.8%) 187 (94.4%) 70 (93.3%)
Taking codeine† 1 N (%) 73 (26.2%) 35 (25.7%) 38 (26.6%) 50 (25.5%) 20 (26.7%)
Taking codeine 2 N (%) 58 (20.6%) 28 (20.4%) 30 (20.8%) 40 (20.2%) 16 (21.3%)
Confirmed
codeine analgesic
2 N (%) 43 (15.3%) 18 (13.1%) 25 (17.4%) 25 (12.6%) 16 (21.3%)
*One patient missed observation
†Two patients missed observations at Visit 1
PRM, prolonged release melatonin; SD, standard deviation
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Page 8 of 18Table 3 Effects of 3 weeks treatment with prolonged release melatonin (PRM) and placebo on sleep diary-recorded
sleep latency in the low excretors and the elderly patients
Treatment Treatment effect difference PRM - placebo; (95% confidence
interval)
P value*
effect PRM versus
placebo
PRM Placebo
Low excretor population
N 86 86
Baseline: mean (SD) 74.1
(54.9)
75.5
(58.5)
Treatment: mean (SD) 65.1
(59.9)
66.5
(51.6)
Change from baseline: mean
(SD)
-9.0 (50.5) -9.0
(48.7)
-0.6 (-14.0, 12.7) 0.924
65-80 year population
N 137 144
Baseline: mean (SD) 76.7
(63.7)
72.5
(51.4)
Treatment: mean (SD) 57.6
(51.8)
70.9
(54.0)
Change from baseline: mean
(SD)
-19.1
(47.3)
-1.7
(47.8)
-15.6 (-25.3, -6.0), 0.002
*Linear regression model with terms for treatment (PRM versus placebo), baseline sleep latency and age group (≥65 or <65 - only for the low excretors).
PRM, prolonged release melatonin; SD, standard deviation.
Figure 2 The effect of 3 weeks treatment with prolonged release melatonin (PRM) and placebo on sleep latency in the low excretors
and age 65-80 populations. Mean+standard error of mean values of the change from baseline in sleep latency from the sleep diary following
3 weeks of double blind treatment of low excretors (N = 86 per group) and age 65-80 years (N = 137 PRM, 144 placebo) populations with PRM
and placebo. Asterisks denote significant difference between PRM and placebo groups (**P < 0.01).
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Page 9 of 18during the extension period for these patients show
incremental difference between PRM and placebo with
time of treatment up to 3 months reaching plateau
levels that are maintained to the rest of the 6 months
period (Figure 3). A similar pattern was seen for time
going to bed, with PRM patients going to bed signifi-
cantly earlier than placebo patients (treatment difference
-0.21 h over placebo; 95% CI -0.33 to -0.08, P = 0.002;
Table 6 and Figure 4). There was some indication that
PRM patients also woke up somewhat earlier (treatment
difference -0.12 h; 95% CI -0.24 to 0.00, P = 0.051).
PSQI global scores were lower (improved) in the PRM
group across study visits with significant global treat-
ment effects [-0.70 (-1.17, -0.23) P = 0.003; Table 7].
Consistent with the improvements in quality of sleep
(PSQI global score) and sleep latency (diary), compo-
nents 1 (sleep quality) and 2 (sleep latency) of the PSQI
were significantly lower (improved) in the PRM group
across study visits in patients aged 65-80 years [-0.15
(-0.25, -0.04), P = 0.006, -0.24 (-0.38, -0.10), P =0 . 0 0 1 ] .
PSQI question 2 (sleep latency) was significantly lower
across study visits in the PRM group in the age 65-80
population [-12.1 min (-19.1, -5.1), P = 0.001].
PRM patients aged 65-80 years were significantly more
alert in the morning than placebo patients [-0.10 (-0.19,
-0.01), P = 0.032; Table 6]. The effects of treatment on
morning alertness were enhanced during the long term
period as evidenced by a linear trend in treatment by
visit effects (P = 0.012), with greater benefits for PRM
patients at later visits. CGI-I scores were significantly
lower (improved) across study visits in the PRM group
compared with placebo for these patients [-0.20 (-0.38,
-0.02), P = 0.027; Table 7].
Safety
Treatment period
The safety population consisted of 789 patients who
received at least one dose of study drug. A total of 31
patients reported 42 SAEs during the study, including
one death in a placebo-treated patient. The incidence of
non-fatal SAEs and discontinuations due to AE was low.
One 68-year-old woman treated with PRM had an SAE
of palpitations during the extension period of the study,
which was assessed as possibly drug-related and was
reported as a suspected unexpected serious adverse
reaction (SUSAR). This patient had had a medical his-
tory of palpitations for 3 years prior to the study.
A total of 59 patients discontinued treatment with
study drug due to an AE, 17 (9, 2% PRM; 8, 2% placebo)
in the 3-week treatment period and 42 (30, 5.6% PRM;
Table 4 Sleep diary parameters in the low excretors
Treatment effects
Change from baseline
Mean (SD)
Short term Long term *
Visit 3 Visit 7 Estimate (95% CI)
P-value
Estimate (95% CI)
P-value
NMAX PRM 86 99
Placebo 86 31
Sleep latency PRM -9.0 (50.5) -23.6 (42.1) -0.6 (-14.0, 12.7) -6.7 (-16.4, 3.0)
(min) Placebo -9.0 (48.7) -19.4 (79.5) P = 0.924 P = 0.174
Sleep PRM -0.27 (0.77) -0.31 (1.08) -0.16 (-0.39, 0.08) -0.04 (-0.24, 0.16)
maintenance Placebo -0.12 (1.04) -0.34 (0.71) P = 0.185 P = 0.677
Total sleep PRM 0.34 (0.88) 0.70 (1.00) 9.1 (-6.1, 24.4) 13.1 (1.0, 25.2)
time (h) Placebo 0.20 (0.91) 0.47 (1.18) P = 0.236 P = 0.035
Sleep onset PRM -0.15 (0.89) -0.46 (0.79) -0.08 (-0.33, 0.17) -0.16 (-0.34, 0.03)
(h) Placebo -0.05 (0.80) -0.24 (1.11) P = 0.530 P = 0.096
Sleep offset PRM 0.09 (0.79) 0.08 (0.84) 0.04 (-0.18, 0.25) 0.07 (-0.09, 0.22)
(h) Placebo 0.10 (0.75) 0.20 (1.00) P = 0.744 P = 0.392
Refreshed on PRM -0.09 (0.46) -0.23 (0.43) -0.01 (-0.13, 0.11) -0.03 (-0.12, 0.06)
waking Placebo -0.09 (0.40) -0.29 (0.47) P = 0.830 P = 0.540
Morning PRM -0.14 (0.67) -0.42 (0.65) 0.01 (-0.18, 0.19) -0.06 (-0.19, 0.08)
alertness Placebo -0.19 (0.63) -0.35 (0.73) P = 0.936 P = 0.426
Sleep quality PRM -0.20 (0.67) -0.43 (0.70) -0.04 (-0.24, 0.16) -0.08 (-0.23, 0.06)
Placebo -0.16 (0.70) -0.34 (0.60) P = 0.688 P = 0.266
*The global treatment effect is estimated using a mixed-effect model for repeated measures and takes into account the treatment effect difference over the 26-
weeks (at Visits 3, 4, 5, 6 and 7) sleep latency (diary data) are repeated for completeness
C, confidence interval; SD, standard deviation; PRM, prolonged release melatonin.
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Page 10 of 1812, 6.8% placebo) during the extension period. Overall,
approximately 35% of patients had an AE during the 3-
week treatment period; 75% during the 26-week exten-
sion period and 15% during the run-out period. AE
rates were generally similar in the PRM and placebo
treatment groups (Table 8).
The number and percentage of patients with the most
commonly reported system organ classes in the treat-
ment and extension periods in the safety population are
depicted in Table 9. Nasopharyngitis, arthralgia, diar-
rhoea, lower and upper respiratory tract infections and
headache were the most commonly reported AEs in
both the PRM and placebo-treated groups during both
treatment (3-week and 26 weeks extension) periods
( T a b l e9 ) .T h e r ew a sn oe v i d e n c eo fad i f f e r e n c e
between treatments or age groups in the type and
amount of AEs.
Changes in clinical laboratory results, including endo-
crine function (prolactin, ACTH, T3, free T4, TSH, LH,
FSH), estradiol (women), free and total testosterone
(men),and cortisol (before and after synacthen test),
were generally small and showed no treatment-related
trends. In particular, there were no apparent clinically
relevant differences between the treatment groups in
Table 5 Pittsburgh Sleep Quality Index (PSQI) measures, Clinical Global Impression of Improvement (CGI-I) and World
Health Organization-5 Index in the low excretors
Change from baseline
Mean (SD)
Treatment effects
Short term Long term *
Visit 3 Visit 7 Estimate (95% CI)
P-value
Estimate (95% CI)
P-value
NMAX PRM 86 101
Placebo 86 31
PSQI PRM -2.13 (2.89) -3.78 (3.65) -0.40 (-1.19, 0.38) -0.66 (-1.30, -0.01)
Global score Placebo -1.62 (2.59) -2.94 (2.91) P = 0.313 P = 0.046
PSQI PRM -0.30 (0.83) -0.72 (0.80) -0.02 (-0.22, 0.19) -0.13 (-0.29, 0.02)
Component 1 Placebo -0.26 (0.67) -0.42 (1.06) P = 0.884 P = 0.086
PSQI PRM -0.37 (0.72) -0.90 (1.02) -0.12 (-0.33, 0.10) -0.17 (-0.36, 0.02)
Component 2 Placebo -0.26 (0.71) -0.68 (0.79) P = 0.278 P = 0.080
PSQI PRM -0.50 (0.89) -0.87 (1.04) -0.04 (-0.29, 0.21) -0.13 (-0.33, 0.06)
Component 3 Placebo -0.44 (0.83) -0.65 (0.88) P = 0.735 P = 0.169
PSQI PRM -0.40 (1.09) -0.89 (1.25) 0.09 (-0.20, 0.39) -0.01 (-0.24, 0.21)
Component 4 Placebo -0.45 (0.99) -0.77 (1.12) P = 0.537 P = 0.918
PSQI PRM -0.09 (0.33) -0.01 (0.48) -0.10 (-0.18, -0.03) -0.01 (-0.06, 0.05)
Component 5 Placebo 0.03 (0.32) -0.03 (0.31) P = 0.008 P = 0.811
PSQI PRM 0.00 (0.00) 0.00 (0.00)
††
Component 6 Placebo 0.00 (0.00) 0.00 (0.00)
PSQI PRM -0.47 (0.82) -0.39 (0.99) -0.17 (-0.35, 0.01) -0.06 (-0.17, 0.05)
Component 7 Placebo -0.24 (0.87) -0.39 (0.84) P = 0.067 P = 0.283
PSQI PRM -18.3 (52.4) -41.3 (59.0) -0.2 (-13.2, 12.8) -11.6 (-22.0, -1.1)
Question 2 Placebo -18.5 (51.7) -33.1 (92.2) P = 0.980 P = 0.030
PSQI PRM 0.63 (1.10) 1.11 (1.33) 0.09 (-0.20, 0.38) 0.17 (-0.07, 0.41)
Question 4 Placebo 0.51 (0.94) 0.81 (1.08) P = 0.539 P = 0.164
CGI-I
‡ PRM 3.22 (1.05) 2.50 (1.19) -0.15 (-0.46, 0.16) -0.25 (-0.49, -0.01)
Placebo 3.31 (0.98) 3.06 (1.21) P = 0.339 P = 0.042
WHO-5 PRM 1.27 (3.53) 1.79 (4.27) 1.21 (0.22, 2.20), 0.91 (0.16, 1.66)
Index Placebo -0.03 (3.45) 1.06 (3.56) P = 0.016 P = 0.017
Mean (standard deviation; SD) changes from baseline at Visits 3 and 7, with estimates of short-term treatment effect (linear regression model, adjusted for
baseline value and age) and long-term treatment effect (mixed effects regression model, adjusted for baseline value, age and visit; global treatment effect
reported).
*Global treatment effect is estimated using a mixed-effect model for repeated measures and takes into account the treatment effect difference over the 26-
weeks (at Visits 3, 4, 5, 6 and 7).
†Regression models for PSQI Component 6 not fitted due to lack of variability in the data.
‡Data shown are for values recorded at each visit, and regression models do not include baseline adjustment, since CGI-I at baseline not defined.
CI, confidence interval.
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Page 11 of 18mean change from baseline for any endocrine function
assessment for men aged > 50 and < 50 or post-meno-
pause and pre-menopause women. In general, there
were no apparent differences between treatment groups
in vital signs, ECG, physical examination or any of the
safety outcomes measured.
Withdrawal period
There was no evidence of a difference between treat-
ment groups in the proportion of subjects experiencing
new symptoms on the Tyrer questionnaire after the
withdrawal period (secondary efficacy endpoint), which
was about 28% in both groups (P = 0.881) indicating no
withdrawal effects. However, placebo patients tended to
exhibit more symptoms assessed by the Tyrer question-
naire at the end of both the extension period (treatment
week 29; 49.2% reports on symptoms in the PRM versus
59.5% in the placebo group) and the end of the 2 weeks
run-out period (withdrawal; 44.0% reports on symptoms
in the PRM versus 50.4% in the placebo group). This
was even more pronounced in the older population
(aged 65-80) with 53.7% symptoms recorded in the
PRM at the end of the extension period (treatment
week 29) versus 67.7% in the placebo group and 45.4%
symptoms recorded in the PRM versus 64.5% in the pla-
cebo group at the end of the 2 weeks run-out period
(withdrawal). In this population the proportion of
subjects experiencing new symptoms on the Tyrer
questionnaire after the withdrawal period was 24.5% in
the PRM group versus 35.5% in the placebo group.
Discussion
To our knowledge, this is the first double-blind, pla-
cebo-controlled randomized trial evaluating the long-
term effects of melatonin treatment in insomnia
patients. A total of 722 of the 791 randomized patients
were analysed in the full analysis set in this study with a
DSM IV diagnosis of primary insomnia and a sleep
latency of at least 20 min (mean sleep latency 74 min).
The main aim of this study, based on the shortening
of sleep latency, was to determine if endogenous melato-
nin level regardless of age is useful to predict response
to PRM therapy. The results provide evidence that
Table 6 Sleep Diary parameters in the 65-80 age group
Treatment effects
Change from baseline
Mean (SD)
Short term Long term *
Visit 3 Visit 7 Estimate (95% CI)
P-value
Estimate (95% CI)
P-value
NMAX PRM 137 159
Placebo 144 61
Sleep latency PRM -19.1 (47.3) -25.9 (46.4) -15.6 (-25.3, -6.0) -14.5 (-21.4, -7.7)
(min) Placebo -1.7 (47.8) -8.3 (61.5) P = 0.002 P < 0.001
Sleep PRM -0.24 (0.80) -0.31 (0.94) -0.17 (-0.33, 0.00) -0.09 (-0.22, 0.03)
maintenance Placebo -0.09 (0.78) -0.20 (0.70) P = 0.046 P = 0.148
Total sleep PRM 0.34 (0.75) 0.64 (0.99) 7.0 (-3.4, 17.4) 7.5 (-0.7, 15.7)
time (h) Placebo 0.20 (0.79) 0.41 (1.06) P = 0.186 P = 0.073
Sleep onset PRM -0.22 (0.80) -0.41 (0.75) -0.22 (-0.39, -0.05) -0.21 (-0.33, -0.08)
(hours) Placebo 0.00 (0.71) -0.12 (1.06) P = 0.012 P = 0.002
Sleep offset PRM 0.03 (0.81) 0.03 (0.84) -0.16 (-0.33, 0.02) -0.12 (-0.24, 0.00)
(h) Placebo 0.19 (0.79) 0.21 (0.91) P = 0.076 P = 0.051
Refreshed on PRM -0.10 (0.36) -0.22 (0.42) 0.00 (-0.08, 0.08) -0.06 (-0.12, 0.00)
waking Placebo -0.09 (0.37) -0.11 (0.42) P = 0.994 P = 0.053
Morning PRM -0.18 (0.52) -0.36 (0.69) -0.04 (-0.16, 0.07) -0.10 (-0.19, -0.01)
alertness Placebo -0.11 (0.51) -0.09 (0.60) P = 0.453 P = 0.032
PRM -0.20 (0.56) -0.39 (0.71) -0.06 (-0.19, 0.07) -0.08 (-0.18, 0.01)
Sleep quality Placebo -0.12 (0.57) -0.17 (0.54) P = 0.356 P = 0.082
Mean (SD) changes from baseline at Visits 3 and 7, with estimates of short-term treatment effect (linear regression model, adjusted for baseline value and age)
and long-term treatment effect (mixed effects regression model, adjusted for baseline value, age and visit; global treatment effect reported)
Mean (standard deviation; SD) changes from baseline at Visits 3 and 7, with estimates of short-term treatment effect (linear regression model, adjusted for
baseline value and age) and long-term treatment effect (mixed effects regression model, adjusted for baseline value, age and visit; global treatment effect
reported)
*Global treatment effect is estimated using a mixed-effect model for repeated measures and takes into account the treatment effect difference over the 26-
weeks (at Visits 3, 4, 5, 6 and 7) sleep latency (diary data) are repeated for completeness.
CI, confidence interval
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Page 12 of 18short-term (3 weeks) treatment with PRM is effective in
elderly patients. Notably, the age cutoff for patients >65
years used for the primary analysis in this study, does
not preclude response to PRM in younger patients.
Rather, there is sufficient evidence in previous studies
[21-25] for an equal or greater response to PRM in
patients aged 55 and older. Thus, further studies of the
age cut-off for response are warranted.
The study also indicates that low melatonin excretion
level regardless of age is not useful in predicting the
response to PRM in insomnia. It is well known that
melatonin levels vary widely between individuals [17,34].
There is also evidence that, regardless of initial levels at
young age, there is a reduction in melatonin levels with
age [11-18]. It has thus been proposed that a melatonin
deficiency should be viewed as relative to melatonin
levels at young age (a decline from 120 pg/mL when
young to 40 pg/mL when old) rather than as absolute
levels measured at old age [35]. The individual decline
in melatonin production capability may better corre-
spond to poor quality of sleep in insomnia patients than
absolute melatonin levels [18,34]. Thus, the strong find-
ing of age related efficacy may reflect within patient
reduction in melatonin levels which is masked in the
younger age groups by the wide variability in normal
levels.
Table 7 Pittsburgh Sleep Quality Index (PSQI) measures, Clinical Global Impression of Improvement (CGI-I) and World
Health Organization-5 Index in the 65-80 age group
Change from baseline
Mean (SD)
Treatment effects
Short term Long term *
Visit 3 Visit 7 Estimate (95% CI)
P-value
Estimate (95% CI)
P-value
NMAX PRM 136 164
Placebo 144 62
PSQI PRM -1.86 (2.93) -3.34 (3.37) -0.64 (-1.25, -0.02) -0.70 (-1.17, -0.23)
Global score Placebo -1.19 (2.53) -2.08 (2.92) P = 0.042 P = 0.003
PSQI PRM -0.32 (0.71) -0.59 (0.82) -0.09 (-0.23, 0.05) -0.15 (-0.25, -0.04)
Component 1 Placebo -0.19 (0.65) -0.34 (0.85) P = 0.217 P = 0.006
PSQI PRM -0.43 (0.87) -0.75 (0.99) -0.23 (-0.41, -0.04) -0.24 (-0.38, -0.10)
Component 2 Placebo -0.22 (0.74) -0.52 (0.95) P = 0.018 P = 0.001
PSQI PRM -0.48 (0.89) -0.86 (1.08) -0.10 (-0.29, 0.10) -0.10 (-0.25, 0.05)
Component 3 Placebo -0.40 (0.89) -0.65 (0.96) P = 0.328 P = 0.177
PSQI PRM -0.32 (0.96) -0.79 (1.22) -0.05 (-0.27, 0.17) -0.10 (-0.26, 0.06)
Component 4 Placebo -0.29 (1.04) -0.47 (1.05) P = 0.638 P = 0.236
PSQI PRM 0.01 (0.41) -0.04 (0.43) -0.05 (-0.13, 0.02) 0.00 (-0.05, 0.05)
Component 5 Placebo 0.03 (0.39) -0.02 (0.42) P = 0.162 P = 0.973
PSQI PRM -0.01 (0.12) 0.01 (0.18)
††
Component 6 Placebo 0.00 (0.00) 0.00 (0.00)
PSQI PRM -0.30 (0.95) -0.31 (0.94) -0.04 (-0.19, 0.11) -0.07 (-0.17, 0.02)
Component 7 Placebo -0.12 (0.69) -0.10 (0.86) P = 0.636 P = 0.137
PSQI PRM -25.4 (50.9) -32.7 (49.3) -13.7 (-23.5, -3.9) -12.1 (-19.1, -5.1)
Question 2 Placebo -8.9 (48.0) -19.0 (65.8) P = 0.006 P = 0.001
PSQI PRM 0.58 (1.03) 1.05 (1.29) 0.10 (-0.13, 0.33) 0.14 (-0.04, 0.32)
Question 4 Placebo 0.48 (1.00) 0.71 (1.08) P = 0.381 P = 0.120
PRM 3.34 (1.17) 2.70 (1.17) -0.12 (-0.37, 0.14) -0.20 (-0.38, -0.02)
CGI-I
‡ Placebo 3.54 (0.85) 3.19 (1.11) P = 0.364 P = 0.027
WHO-5 PRM 1.02 (3.73) 1.51 (4.05) 0.42 (-0.34, 1.18), 0.55 (-0.02, 1.13)
Index Placebo 0.27 (3.15) 0.35 (4.21) P = 0.281 P = 0.058
Mean (standard deviation; SD) changes from baseline at Visits 3 and 7, with estimates of short-term treatment effect (linear regression model, adjusted for
baseline value and age) and long-term treatment effect (mixed effects regression model, adjusted for baseline value, age and visit; global treatment effect
reported)
*Global treatment effect is estimated using a mixed-effect model for repeated measures and takes into account the treatment effect difference over the 26-
weeks (at Visits 3, 4, 5, 6 and 7).
†Regression models for PSQI Component 6 not fitted due to lack of variability in the data.
‡ Data shown are for values recorded at each visit, and regression models do not include baseline adjustment, since CGI-I at baseline not defined.
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Figure 3 Sleep latency during the treatment period. Mixed Effect Model for Repeated Measures (MMRM) predicted mean values (mean +
standard error of mean) for sleep latency from the sleep diary, at baseline and weeks 3-29 of the double blind treatment periods, in those aged
65-80 years. Asterisks denote significant difference between prolonged release melatonin and placebo groups (*P < 0.05 ** P < 0.01). Numbers
of patients analysed in each treatment time point are depicted
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Figure 4 Time of going to bed during the treatment period. MMRM-predicted mean values (mean + standard error of mean) for time going
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(ITT) 65-80 population. Asterisks denote significant difference between prolonged release melatonin and placebo groups (*P < 0.05 ** P < 0.01).
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old patients are very similar to those found with current
hypnotic drugs, including those developed primarily for
patients with difficulty falling asleep [36-38]. The PRM
efficacy reported in the present study is not only statisti-
cally significant but also clinically relevant. Furthermore,
there were no signs of tolerance, as there was no reduc-
tion in benefit during the long-term treatment.
A limitation of this study was the lack of polysomno-
graphic or actigraphic data. However, in clinical practice,
patients with insomnia do not receive overnight sleep
recordings and physicians base the success of any given
treatment on patient reports of improved sleep and well
being [39]. Furthermore actigraphy is considered less use-
ful for sleep latency in insomnia [40]. Evidently the hypno-
tic effect of PRM in this study as measured by subjective
means is very much like that documented in the sleep
laboratory and previous studies using clinical assessments
[24,25]. Therefore, the subjective improvements in this
study are relevant and allow a better understanding the
efficacy of PRM in the treatment of insomnia.
The magnitude of the effects of PRM on sleep latency
documented in the present study, agree well with the
results of the previous clinical trials with this drug [24],
including a sleep laboratory study using polysomnogra-
phy [25] in patients aged 55 and older. The observed
effect on sleep latency for patients aged 65-80 years
(-15.6 min; 95% CI -25.3 to -6.0, P = 0.002) was larger
than would be predicted according to the published
meta-analysis on efficacy of exogenous melatonin for
primary insomnia [-7.2 min (95% CI -12.0, -2.4; n = 12)]
[20] which was predominantly based on studies in
younger patients and their use of immediate release
preparations. The apparently weaker efficacy profile of
3 weeks treatment with PRM in the low excretors
(18-80 years) may thus be due to the younger patients
(aged <55 years) in the population.
Table 8 Number (%) of patients who had an adverse
event (AE) in any category in the treatment and
extension periods, safety population.
Category of AE Treatment period Extension period
PRM Placebo PRM Placebo
No. of patients 394 395 534 177
Any AE 136
(34.5%)
142
(35.9%)
394
(73.8%)
136
(76.8%)
Any SAE 1 (0.3%) 3 (0.8%) 15 (2.8%) 9 (5.1%)
SAE leading to
death
0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.6%)
DAE 9 (2.3%) 8 (2.0%) 30 (5.6%) 12 (6.8%)
Drug-related AE* 17 (5.3%) 19 (6.1%) 56 (12.9%) 24 (17.3%)
Drug-related SAE* 0 (0.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%)
Percentages based on number of patients in the safety population for each
treatment group.
*Assessed by the investigator as definitely, probably or possibly related to
study drug.
SAE, serious adverse event; DAE, premature discontinuation of treatment with
investigational product due to an AE; PRM, prolonged release melatonin.
Table 9 Number (%) of patients with the most commonly reported system organ classes in the treatment and
extension periods, safety population.
System organ class Treatment period Extension period
PRM(n = 394) Placebo(n = 395) PRM(n = 534) Placebo(n = 177)
Infections and infestations 38 (9.6) 43 (10.9) 176 (33.0) 60 (33.9)
Gastrointestinal disorders 18 (4.6) 31 (7.8) 113 (21.2) 37 (20.9)
Musculoskeletal and connective tissue disorders 21 (5.3) 21 (5.3) 113 (21.2) 34 (19.2)
Nervous system disorders 19 (4.8) 23 (5.8) 47 (8.8) 19 (10.7)
Respiratory, thoracic and mediastinal disorders 12 (3.0) 16 (4.1) 47 (8.8) 18 (10.2)
Skin and subcutaneous tissue disorders 12 (3.0) 9 (2.3) 43 (8.1) 13 (7.3)
Injury, poisoning and procedural complications 8 (2.0) 2 (0.5) 35 (6.6) 13 (7.3)
Renal and urinary disorders 9 (2.3) 4 (1.0) 29 (5.4) 7 (4.0)
General disorders and administration site disorders 5 (1.3) 5 (1.3) 28 (5.2) 16 (9.0)
Investigations 5 (1.3) 7 (1.8) 24 (4.5) 9 (5.1)
Eye disorders 5 (1.3) 1 (0.3) 20 (3.7) 6 (3.4)
Psychiatric disorders 5 (1.3) 4 (1.0) 17 (3.2) 13 (7.3)
Vascular disorders 2 (0.5) 0 (0) 16 (3.0) 5 (2.8)
Cardiac disorders 0 (0) 1 (0.3) 15 (2.8) 2 (1.1)
Ear and labyrinth disorders 0 (0) 1 (0.3) 13 (2.4) 2 (1.1)
Reproductive system and breast disorders 3 (0.8) 3 (0.8) 12 (2.2) 1 (0.6)
Metabolism and nutrition disorders 1 (0.3) 2 (0.5) 7 (1.3) 4 (2.3)
Surgical and medical procedures 1 (0.3) 2 (0.5) 7 (1.3) 6 (3.4)
PRM, prolonged release melatonin.
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and daytime parameters withP R M .G l o b a lP S Q Is c o r e s
were improved in PRM patients aged 65 and older, in
both the short and long term. Notably, in this trial,
patients with poor quality of sleep alone were not
entered; patients had also to have some difficulty in fall-
ing asleep to be included. It is therefore not surprising
that in the short term, these overall effects may mainly
be driven by reductions in sleep latency (component 2).
In the long term, however, there was evidence of treat-
ment benefits with respect to both sleep latency and
sleep quality (component 1). There was also evidence of
a delayed effect of PRM treatment in improve morning
alertness (as measured by the diary) over the 6-month
treatment period. Improvement in sleep quality and
morning alertness were consistently found in clinical
trials with PRM [23-25] but not in studies with immedi-
ate release melatonin formulations or the MT1/MT2
melatonin receptor agonist ramelteon [20,38,41]. Such
improvements were also difficult to demonstrate with
other insomnia drugs. Furthermore, the benefit of PRM
in the patients’ overall clinical status (as measured by
t h eC G I - Is c o r e s )i m p r o v e da f t e rl o n g - t e r mt r e a t m e n t ,
in patients aged 65-80 years.
Low excretors also had benefitted from PRM in the
short and long periods. However, we concluded that the
measurement of melatonin metabolite is not helpful in
predicting response to PRM therapy.
A rather unexpected aspect of PRM efficacy is the
incremental nature of the response with time. In addi-
tion, there seems to be a significant urge to advance
bedtime with this treatment. These findings may indi-
cate an effect on the treatment on the internal temporal
order. There is a great deal of evidence indicating that
aging is characterized by a progressive deterioration of
circadian timekeeping, including loss of SCN melatonin
receptors [14,42-44]. Functional disturbances of SCN
circadian activity may start already around the age of
50, as evidenced by a decrease in vasopressin rhythmic
function, in the expression of melatonin receptors in the
SCN and in melatonin production compared to younger
adults [14,16,43]. Consequently, there is disorganization
of the internal temporal order [12,44]. PRM treatment
has been shown to delay the nocturnal cortisol produc-
tion in elderly insomnia patients towards the morning
[45], improve blood pressure rhythms [46] and, as
shown here, progressively advance time to bed in those
aged 65-80 years old in addition to the shortening of
sleep latency. Improvement in internal temporal order
with PRM may explain why the treatment effects are
more prominent in older patients and there is a gradual
development of response over days or weeks [25].
Further research will aim at investigating whether the
evolution of response to PRM represents a re-activation
of the circadian system or reinforcement of responsive-
ness to melatonin.
There were no new or unexpected safety findings fol-
lowing short- and long-term treatment with PRM,
except for one case of palpitations. The safety profile of
the PRM treatment group was very similar to placebo
with respect to the incidence and type of AEs, the
results of clinical laboratory tests, vital signs, ECG and
physical examination and endocrine function including
prolactin, ACTH, T3, free T4, TSH, LH, FSH, oestradiol
(women), free and total testosterone (men) and cortisol
(before and after synacthen test). There were no with-
drawal effects after ceasing long-term treatment with
PRM, as assessed by the Tyrer questionnaire scores or
incidences of AEs during the run-out period. The
improvements in sleep parameters decreased during the
run-out period but had not reached baseline values by
the end of this period.
Conclusions
Patients aged 65 years and over with primary insomnia
are likely to have a good response to melatonin therapy
and the response will increase and be sustained over a
period of 6 months. Further studies of the age cut-off
for response are warranted. A low melatonin excretion
level, regardless of age, is not useful in predicting
response to PRM in insomnia and this is probably due
to wide variation among individuals. Thus, clinicians do
not require melatonin measurements prior to treatment.
There were no rebound or withdrawal effects upon the
discontinuation of PRM following long-term use.
The safety and efficacy profile of PR melatonin, as
demonstrated in this study, supports its continuous use
for 6 months in the treatment of primary insomnia in
the target population.
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